Loading patent…
AssigneeThe Trustees of Columbia University in the City of New York
InventorRiccardo Dalla-Favera
Estimating the term…
This invention provides an isolated nucleic acid molecule which encodes immunoglobulin receptor, Immunoglobulin superfamily Receptor Translocation Associated, IRTA, protein. Provided too, are the IRTA proteins encoded by the isolated nucleic acid molecules, IRTA1, IRTA2, IRTA3, IRTA4 or IRTA5 proteins, having the amino acid sequences set forth in any of FIG. 18A, 18B-1-18B-3, 18C-1-18C-2, 18D-1-18D-2 or 18E-1-18E-2. Oligonucleotides of the isolated nucleic acid molecules are provided. Antibodies directed to an epitope of a purified IRTA1, IRTA2, IRTA3, IRTA4 or IRTA5 proteins are also provided, as are pharmaceutical compositions comprising such antibodies or oligonucleotides. Methods for detecting a B cell malignancy in a sample from a subject; diagnosing B cell malignancy in a sample from a subject; detecting human IRTA protein in a sample; and treating a subject having a B cell cancer are also provided.
A purified antibody directed to a human IRTA3 protein, wherein the amino acid sequence of the human IRTA3 protein is set forth in SEQ ID NO:5.
A composition comprising a pharmaceutically acceptable carrier and an antibody which binds to a human IRTA3 protein, wherein the antibody is conjugated to a therapeutic agent selected from the group consisting of a radioisotope, a toxin, a toxoid, or a chemotherapeutic agent, wherein the amino acid sequence of the human IRTA3 protein is set forth in SEQ ID NO:5 and wherein the antibody conjugated to the therapeutic agent is present in an amount effective to bind cancer cells expressing IRTA3 protein so as to prevent growth of the cancer cells.
Dependencies are inferred from the claim text.